西地那非减少足月产时胎儿窘迫手术产:2期随机对照试验
这项在澳大利亚布里斯班Mater Mother's Hospital开展的2期双盲随机对照试验,将300名足月早期临产或计划引产的孕妇等比例随机分配至口服西地那非50mg每8小时(最多150mg)组或安慰剂组。结果显示西地那非使产时胎儿窘迫所致急诊手术产风险降低51%(18% vs 36.7%;
要点
- 西地那非使产时胎儿窘迫急诊手术产风险降低51%(RR 0.49,95%CI 0.33-0.73)。
- 西地那非使胎粪污染羊水或病理性胎心监护风险降低43%(RR 0.57)。
- 对新生儿不良结局的影响尚不确定(RR 0.97,95%CI 0.62-1.50)。
核心结论
- 西地那非可降低足月产时胎儿窘迫所致的急诊手术产风险,但需更大规模3期试验评估母儿影响后方可常规推荐。
研究设计与样本
- 2期双盲随机对照试验,在澳大利亚布里斯班Mater Mother's Hospital纳入300名足月早期临产或计划引产孕妇,等比例随机分配至口服西地那非50mg每8小时(最多150mg)组或安慰剂组,按意向性分析。
主要发现
- 两组胎儿及子宫胎盘灌注指数无差异,但仅在71名妇女中进行了测定。
- 脐血中仅检测到3.6%的母体西地那非或其代谢物水平,母体不良事件无差异。
关键数值与推荐
- 足月早期临产或计划引产孕妇口服西地那非50mg每8小时,最多150mg。
- 产时胎儿监护遵循澳大利亚和新西兰妇产科皇家学院(RANZCOG)指南。
- 主要结局为因产时胎儿窘迫的急诊手术产和胎儿及子宫胎盘灌注平均指数。
临床怎么用
- 目前不应常规使用西地那非预防产时胎儿窘迫手术产,需等待3期试验结果。
- 对于足月临产孕妇,西地那非可能作为降低手术产风险的潜在干预,但需个体化评估。
局限性
- 胎儿及子宫胎盘灌注指数仅在71名妇女中测定,样本量有限。
- 对胎儿头皮采血率和新生儿不良结局的影响不确定。
- 作者认为需要更大规模3期试验评估母儿安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Sildenafil citrate is a vasodilator used in erectile dysfunction and pulmonary hypertension. We tested whether it reduces emergency operative births for fetal compromise and improves fetal or uteroplacental perfusion in labor in a phase 2 double-blind randomized controlled trial. STUDY DESIGN: Women at term in early labor or undergoing scheduled induction of labor at Mater Mother's Hospital, Brisbane, Australia, were randomly allocated 50 mg of sildenafil citrate orally 8 hourly up to 150 mg or placebo. Intrapartum fetal monitoring followed Royal Australian and New Zealand College of Obstetricians and Gynaecologists guidelines. Primary outcomes were (1) emergency operative birth (by cesarean delivery or instrumental vaginal birth) for intrapartum fetal compromise and (2) mean indices of fetal and uteroplacental perfusion using Doppler ultrasound. Analysis was by intention-to-treat. TRIAL REGISTRATION NUMBER: ANZCTRN12615000319572 RESULTS: Between September 2015 and January 2019, 300 women were randomized equally to sildenafil citrate or placebo. Sildenafil citrate reduced the risk of emergency operative birth by 51% (18% vs 36.7%; relative risk, 0.49, 95% confidence interval, 0.33-0.73, P=.0004, number needed to treat = 5 [3-11]). There was no difference in indices of fetal and uteroplacental perfusion, but these were ascertained in only 71 women. Sildenafil citrate reduced the risk of meconium-stained liquor or pathologic fetal heart rate patterns by 43% (25.3% vs 44.7%; relative risk, 0.57, 95% confidence interval, 0.41-0.79, P=.0005), but its effects on fetal scalp sampling rates (2.0% vs 6.7%; relative risk, 0.30, 95% confidence interval, 0.08-1.07, P=.06) and adverse neonatal outcome (20.7% vs 21.3%; relative risk, 0.97, 95% confidence interval, 0.62-1.50, P=.89) were inconclusive. Only 3.6% of maternal levels of sildenafil citrate or its metabolite were detected in cord blood. No differences in maternal adverse events were seen. CONCLUSION: Sildenafil citrate reduced operative birth for intrapartum fetal compromise, but much larger phase 3 trials of its effects on mother and child are needed before it can be routinely recommended.
引用
- Turner J, Dunn L, Tarnow-Mordi W, et al. Safety and efficacy of sildenafil citrate to reduce operative birth for intrapartum fetal compromise at term: a phase 2 randomized controlled trial. Am J Obstet Gynecol. 2020. PMID: 31978434. doi:10.1016/j.ajog.2020.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。